Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

Executive Summary

Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals

You may also be interested in...

Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree

Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.

Ocera Forwards Liver Disease Drug After Reverse Merger With Tranzyme

Ocera went public by completing a reverse merger with the failing biotech Tranzyme, then completed a $20 million PIPE financing that positions it to begin a Phase IIb trial studying its lead drug for a rare liver disease.

Gilead Leads Biotech Rebound In 2003: Product Stories Play Well

Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts